AstraZeneca’s (AZN) Buy Rating Reiterated at Berenberg Bank

Berenberg Bank reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research note published on Wednesday morning,Digital Look reports. Berenberg Bank currently has a £175 price objective on the biopharmaceutical company’s stock.

A number of other research firms also recently commented on AZN. Royal Bank Of Canada reiterated an “outperform” rating and issued a £145 price objective on shares of AstraZeneca in a report on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a £117 target price on shares of AstraZeneca in a research note on Tuesday, September 29th. Jefferies Financial Group reaffirmed a “buy” rating and issued a £175 price target on shares of AstraZeneca in a report on Wednesday, September 9th. Finally, Citigroup increased their price target on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and an average price target of £153.57.

AstraZeneca Price Performance

AZN stock opened at £119.98 on Wednesday. The business’s 50-day moving average is £120.45 and its two-hundred day moving average is £131.98. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. The firm has a market capitalization of £186.08 billion, a P/E ratio of 17.96, a P/E/G ratio of 0.86 and a beta of 0.20. AstraZeneca has a 1 year low of £114.04 and a 1 year high of £157.32.

Insider Activity

In related news, insider Michel Demare purchased 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The shares were purchased at an average price of £121.21 per share, for a total transaction of £303,025. 0.15% of the stock is currently owned by corporate insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.